Aduro Biotech Chief Scientific Officer to Highlight the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Aduro Biotech Chief Scientific Officer to Highlight the Potential of STING Activation in Cancer Immunotherapy in a Major Symposium at the 2016 American Association for Cancer Research Annual Meeting

BERKELEY, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO ), today announced that the company’s chief scientific officer, Thomas W. Dubensky, Jr., Ph.D., will be a featured speaker at the American Association for Cancer Research (AACR) 2016 Annual Meeting being held April 16-20 in New Orleans, Louisiana.  Dr. Dubensky’s presentation is part of a Major Symposium, “Cancer Immunotherapy: Small Molecule Approaches,” taking place on April 20, 2016, during which he will highlight Aduro’s landmark first-in-human immunotherapeutic approach in cancer to target the Stimulator of Interferon Genes (STING) pathway.

The presentation will focus on ADU-S100, a novel synthetic cyclic dinucleotide (CDN) that is one of a family of proprietary small molecules being developed by Aduro that broadly activates the human STING receptor. STING is expressed in immune cells that are present in the tumor microenvironment (TME) and is a central and potent mediator of the innate immune response, a necessary step in the development of effective tumor-specific immunity. Activation of the STING pathway has been shown to correlate with infiltration of lymphocytes and a “T-cell inflamed TME” in patients with melanoma. Stimulation of STING induces signaling through several innate immune response pathways, resulting in the expression of various interferons, cytokines and T cell recruitment factors that amplify and strengthen immune activity. Dr. Dubensky will discuss preclinical data demonstrating that the direct engagement of STING through the intratumoral injection of ADU-S100 resulted in effective, durable and systemic anti-tumor activity. The data suggest that the resulting tumor regression is due to an acute pro-inflammatory cytokine response and induction of tumor-specific CD8 + T cell immunity.  Preclinical data will be presented which also demonstrate the potential synergistic effects of combining ADU-S100 and immune checkpoint inhibitors, including anti-PD1.  In addition, Dr. Dubensky will present an overview of the Phase 1 clinical trial to evaluate the safety, tolerability and possible anti-tumor activity of ADU-S100 given by intratumoral injection to patients with advanced cutaneously accessible solid tumors or lymphomas.

“We are excited to share this new research and planned Phase 1 clinical trial, which highlights ADU-S100, Aduro’s lead STING activator candidate, and its translational potential for treating patients with metastatic solid tumors and lymphomas,” said Dr. Dubensky. “Our data suggest that the stimulation of a local immune response in the TME can result in a sustained and effective tumor-specific immune response against metastases throughout the body. This observation reinforces the importance of the STING signaling pathway in cancer immunotherapy and the potential of ADU-S100 to be used alone or in combination treatment approaches for advanced cancer patients.”

Based on these promising preclinical results, Aduro and Novartis, as part of a collaboration focused on STING pathway activator compounds in the field of oncology, will initiate a Phase 1 dose escalation trial with ADU-S100 in patients with cutaneously accessible metastatic solid tumors or lymphomas who have no other treatment options.

Aduro will also be presenting a poster at AACR on Monday, April 18, 2016 titled “STING Activation in the Tumor Microenvironment with a Synthetic Human Cyclic Dinucleotide Leads to Potent Anti-Tumor Immunity.” This will provide additional details on preclinical research showing the effectiveness of ADU-S100 in activating the STING receptor and inducing an immune response across diverse tumor models.

Details of the presentations:

  • Oral Presentation “ SY39-02:  Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity,” Wednesday, April 20, 2016 10:55 AM - 11:20 AM, New Orleans Theater C. Morial Convention Center
  • Poster Presentation “STING Activation in the Tumor Microenvironment with a Synthetic Human Cyclic Dinucleotide Leads to Potent Anti-Tumor Immunity,” Monday, April 18, 2016 8:00 AM - 12:00 PM, Section 24

About Aduro Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's cyclic dinucleotide (CDN) platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com .

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, ADU-S100 and the therapeutic potential for STING activators, the potential for our other product candidates and technology, plans and timing of our clinical trials and the potential for eventual regulatory approval, commercialization and launch of our product candidates. In some cases you can identify these statements by forward-looking words such as  “may,” “will,” “continue,” “anticipate,” “could,” “potential,” “suggest,”  “plan,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our dependence on our lead product candidate, CRS-207, and GVAX Pancreas, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates.  We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our most recent Annual Report on Form 10-K which is on file with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting 925 202 6211 Mike Beyer Sam Brown, Inc. 312 961 2502 press@aduro.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
PAG, HOWL and PSNL Deals Face Fresh Shareholder Checks

Updated Category News Views 38

Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 60

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 63

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 196

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 208

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 17

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 72

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading

Top 5 Most Recently Viewed Articles

INTCO Medical Surges Ahead with 40.6% Revenue Boost

Updated Category News Views 94

Eying Growth: INTCO Medical's Impressive Revenue Surge In today's corporate world, a 40.6% revenue jump over a single half-year isn't something to sneeze at. INTCO Medical, a heavyweight in the disposable glove industry, has done exactly that. The whispers out of Zibo, China, hint at a company that’s firing on all cylinders with $1.03 billion in their pockets for the...

Continue Reading
Taylor Davis Joins Pivot Point Consulting to Boost Client Success

Updated Category News Views 108

Pivot Point Consulting brought in a big player back then: Taylor Davis, the former President of KLAS Research. He wasn't just some guy; he founded the KLAS Arch Collaborative. This move was about shaking things up in healthcare consulting during tough times. Desks were buzzing over this power shift. In his past gig at KLAS, Davis was instrumental in creating standards...

Continue Reading
Entegris' Financial Highlights and Outlook for 2025

Updated Category News Views 971

Entegris Reports Strong Fourth Quarter Performance Entegris, Inc. (NASDAQ: ENTG) has recently released its financial results marking a robust conclusion to the fiscal year. The company's fourth-quarter performance surpassed projections for both revenue and non-GAAP earnings per share. CEO Insights on Market Dynamics Bertrand Loy, the President and CEO of Entegris,...

Continue Reading
Top Dividend Stocks Insiders Increased Their Investments In January

Updated Category News Views 109

Insider Purchasing Trends in Dividend Stocks January unveiled strong insider buying activity across various dividend-paying stocks, pointing to confidence in future growth. Leaders in this buying spree were notable companies including Lakeland Industries (NASDAQ: LAKE), York Water (NASDAQ: YORW), and RLI Corp (NYSE: RLI). Such movements may indicate these stocks are worth...

Continue Reading
FDA Approves Omvoh for Crohn's Disease: A New Era in Treatment

Updated Category News Views 515

FDA Approves Omvoh for Crohn's Disease Eli Lilly and Company (NYSE: LLY) proudly announces the FDA's approval of Omvoh (mirikizumab-mrkz), a groundbreaking treatment for adults suffering from moderately to severely active Crohn's disease. This marks a significant advancement, as Omvoh is now recognized for treating not just this debilitating condition but also ulcerative...

Continue Reading